Mar 09, 2022 / NTS GMT
Presentation
Mar 09, 2022 / NTS GMT
=====================
Corporate Participants
=====================
* René C. Goehrum
BioSyent Inc. - Chairman, CEO & President
=====================
RenéC. Goehrum - BioSyent Inc. - Chairman, CEO & President
Hello, and welcome to the Q4 and fiscal year 2021 results presentation for BioSyent Inc. My name is René Goehrum, and I'm the President and CEO of the company.
I'm going to start today's presentation with a look at our revenue, EBITDA and net income after tax for the quarter ended December 31, 2021. As you can see, our sales reached just above $7.2 million in the quarter, which represented a 26% increase versus the year ago. Our EBITDA was just above $2.6 million, representing 136% increase to the year ago. And our net income after tax was just below $1.9 million, 182% of the year ago period.
So the fourth quarter represented our 46th consecutive profitable quarter, and that revenue growth was driven across the business. So our Canadian Pharma business was up 20%. Our
Q4 2021 Biosyent Inc Earnings Presentation Transcript
Mar 09, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers